Category Archives: Other

Gansu Screens Ninth Batch of Drug Sunshine Listing Applications – Only 229 of 595 Pass Formal Review as Appeal Window Closes

Lanzhou, China – 18 Sep 2026 – The Gansu Public Resources Trading Center publicized the formal review results of the ninth batch of new drug sunshine listing applications for 2026, disclosing that of 595 products submitted through the national joint review mechanism (联审通办) and the provincial bidding‑and‑procurement management subsystem as of 10 September 2026, only 229 qualified for platform listing while 366 failed the screening. The publicity period runs 20–22 September 2026, with online appeals due by 24:00 on 22 September 2026.

Policy Snapshot

ItemDetail
AgencyGansu Public Resources Trading Center; supervised by the Gansu Provincial Healthcare Security Bureau
DocumentPublicity of Formal Review Results – Ninth Batch of New Drug Sunshine Listings, 2026
Legal BasisGansu Service Guide for the Drug & Medical Consumables Procurement Management Subsystem (v1.0); Gansu Drug Listing/Delisting Rules
Applications Received595 (national joint review + provincial subsystem, as of 10 Sep 2026)
Passed Formal Review229 (≈ 38.5 % pass rate)
Failed Formal Review366 – itemized in the annexed publicity table (.xls)
Publicity Period20–22 Sep 2026
Appeal Deadline24:00, 22 Sep 2026, online only
ContactsBusiness: 0931‑2909290 / 2909266 / 2909265; Supervision: 0931‑8127609 (Provincial Healthcare Security Bureau)

Review Results & Compliance Requirements

  • Formal Review Outcomes: The 229 qualifying products will proceed to sunshine listing on the provincial platform, subject to completion of the publicity period; the 366 rejected products are listed in the annexed Formal Review Results Publicity Table, giving affected manufacturers a clear, product‑level basis for appeal.
  • Price Declaration Undertakings: Listing prices are self‑declared by enterprises under the good‑faith principle and must not exceed Gansu’s provincial price‑management requirements – placing documentation and pricing integrity squarely on applicants.
  • Cross‑Province Price‑Linkage Rule: If a listed drug’s price is reduced in any other province, the manufacturer must proactively apply for a matching price cut in Gansu within one month – failure to do so triggers suspension of trading qualification, extending the nationwide price‑linkage discipline into Gansu’s procurement channel.
  • Appeals Strictly Online: Objections must be filed via the “Appeal & Query” module under the “New Drug Listing Application” menu of the Gansu National Healthcare Insurance Information Platform procurement subsystem; paper and email submissions are not accepted, and non‑conforming filings will be rejected with any resulting losses borne by the enterprise.

Market Impact & Outlook

  • Selective Gatekeeping: A ≈ 38.5 % pass rate (229 of 595) signals rigorous formal screening in Gansu, reinforcing that completeness and accuracy of submission dossiers – not price alone – determine platform access.
  • National‑Provincial Convergence: The batch combined applications from the national joint review mechanism with the provincial subsystem, reflecting China’s ongoing integration of drug procurement access points across provinces.
  • Pricing Discipline Tightening: The one‑month cross‑province price‑adjustment obligation, backed by trading suspension, aligns Gansu with the hardening nationwide enforcement of external‑reference pricing for listed drugs.
  • Immediate Action Window: With the publicity period and appeal deadline both closing on 22 September 2026, manufacturers among the 366 rejected products face a same‑week turnaround to challenge results or prepare compliant resubmissions in future batches.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding appeal outcomes, listing approvals, price‑adjustment obligations, and trading‑qualification status for drug products in Gansu Province. Actual results may differ due to risks including appeal handling decisions, enterprise remediation progress, and subsequent policy adjustments by the Gansu Public Resources Trading Center and the Provincial Healthcare Security Bureau.-China Health Reform Pulse

Policy Source: https://sjfz.ggzyjy.gansu.gov.cn:19002/#/details-medicine?params=H4sIAAAAAAAAA6tWykxRslIyNLewNDcyNTSyMDc0VaoFAElMeS4WAAAA&pop=true

Guangdong Drug Exchange Center Publishes First September 2026 Batch of Newly Listed Bargaining‑Price Disinfection Products – Batch YJHCGW39‑20260901‑XD Joins Negotiated Procurement Scope for Hospitals Province‑Wide

Guangzhou, China – 17 Sep 2026 – The Guangdong Drug Exchange Center published the products that received no objections during the publicity period in the first batch of September 2026 newly added bargaining‑price listed disinfection products (batch code YJHCGW39‑20260901‑XD), incorporating them into the province’s bargaining‑price listing procurement scope effective immediately, under which medical institutions may procure the products through negotiation at prices no higher than the listed ceiling.

Listing Snapshot

ItemDetail
AuthorityGuangdong Drug Exchange Center (Guangdong Province, China)
PlatformGuangdong Third‑Party Drug Electronic Trading Platform – Medical Consumables Trading System
ActionPublication of newly listed bargaining‑price (议价挂网) disinfection products – first batch, September 2026
BatchYJHCGW39‑20260901‑XD
Publication Date17 September 2026
Product ScopeDisinfection products (消毒产品) declared by enterprises before 10 September 2026, price‑confirmed and listing‑applied via the automatic confirmation workflow; details in the attached product information table
Transaction RuleMedical institutions procure by bargaining at prices not exceeding the listed price

Listing Process & Conditions

  • Automatic Confirmation Workflow: Covered products were declared through the system’s “Price Management – Consumables Bargaining‑Price Listing Addition (Automatic Confirmation Items)” module, where enterprises confirmed price information and submitted listing applications before the 10 September 2026 cut‑off.
  • Publicity‑Period Gate: Only products that received no objections during the publicity period are published in this batch; enterprises are directed to download the attached detailed product list themselves.
  • Deferred Listings: Products with information re‑verification pending or with registration certificates not yet fully effective will be listed only after verification concludes or product status becomes fully effective.
  • Policy Basis: The provincial platform’s announcement on implementing medical consumables listing procurement, the Center’s notice on optimizing routine drug and consumables listing work, and the notice activating the automatic viewing‑and‑confirmation process for bargaining‑price listed consumables price information.

Sector Background

  • Bargaining‑Price Listing (议价挂网): A procurement channel where the listed price serves as a ceiling and hospitals negotiate final prices with suppliers — distinct from fixed‑price centralized procurement, commonly used for competitively supplied consumables and disinfection products.
  • Disinfection Products Category: Managed separately from drugs and medical devices under China’s disinfection product regulations, these products (disinfectants, antiseptics, sanitizing agents for medical use) access hospital channels via provincial platforms once listed.
  • Automation Trend: The automatic price‑confirmation workflow streamlines what was previously manual review — part of Guangdong’s broader digitization of consumables market access with rolling monthly batches.

Market Impact & Outlook

  • Immediate Hospital Access: Products in this batch become procurable across Guangdong’s medical institutions right away, converting listing into commercial opportunity for successful applicants.
  • Price Ceiling Discipline: The “no higher than listed price” bargaining rule anchors hospital negotiations at the confirmed ceiling, reinforcing downward price pressure in the disinfection products segment.
  • Pipeline Watch: Enterprises whose products were held back for re‑verification or pending certificate effectiveness should expect supplementary listings in subsequent batches once conditions are met.
  • Rolling Cadence: The first‑batch numbering (YJHCGW39‑20260901‑XD) reflects a systematic publication schedule — suppliers not in this batch should pre‑position CA credentials, price confirmations and registration documentation ahead of the next monthly cut‑off.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the listing, deferred publication and procurement uptake of bargaining‑price disinfection products in Guangdong. Actual listing status depends on information re‑verification, registration certificate effectiveness and platform processing, and transaction volumes and prices may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100575340429578240

Guangdong Drug Exchange Center Opens Linkage Price Confirmation Window for Listed Drugs – Batch 20260917 Targets Above‑Benchmark VBP Winners and “Four‑Same” Products, With Delisting and Disqualification Risks for Non‑Compliance

Guangzhou, China – 17 Sep 2026 – The Guangdong Drug Exchange Center launched the viewing and confirmation of linkage price information for some listed drugs (Batch 20260917), covering provincial centralized procurement (VBP) winning products priced above other provinces’ winning prices, same‑enterprise products under price‑differential rules, and “Four‑Same” drugs (same generic name, brand, dosage form and specification) listed above the national lowest listing price — with a confirmation window closing at 17:00 on 20 September 2026 and automatic linkage price adjustment, disqualification or delisting for non‑responsive enterprises.

Notice Snapshot

ItemDetail
AuthorityGuangdong Drug Exchange Center (Guangdong Province, China)
ActionLinkage price viewing & confirmation for selected listed drugs
Batch20260917
Product Scope① VBP winners (incl. limited‑volume winners) whose provincial winning price exceeds other provinces’; ② same‑enterprise winners under price‑differential/comparison rules; ③ “Four‑Same” drugs listed above the national lowest listing price (as of 16 Sep 2026; details in system)
Confirmation WindowImmediate – 20 Sep 2026, 17:00
PlatformGuangdong Drug & Medical Consumables Procurement Subsystem (CA certificate login)
Policy BasisNational drug price governance requirements

Confirmation Paths & Consequences

  • Viewing Path (VBP winners above other provinces’ prices): Log in with CA certificate → “Drug Centralized Procurement Management – Drug Price Management – Drug Price Publication – Provincial VBP Winning Product Linkage Price Information Viewing (Batch 20260917).”
  • Confirmation Path (price‑differential winners & “Four‑Same” drugs): Log in with CA certificate → “Drug Price Confirmation – Provincial VBP Winning Products and ‘Four‑Same’ Drug Linkage Price Confirmation (Batch 20260917).”
  • Appeal Mechanism: Enterprises disputing prices must upload appeal materials stamped with the company seal on every page via the designated appeal attachment path within the window; late objections or missing evidence will in principle not be accepted.
  • VBP Winners Above Other Provinces: No objection, or appeal rejected → winning price adjusted downward via linkage automatically.
  • Price‑Differential Winners: Confirm within deadline → linkage adjustment applies; refuse confirmation with appeal rejected, or miss the deadline → winning qualification cancelled per procurement documents.
  • “Four‑Same” Listed Drugs: Confirm within deadline → unified price adjustment across the province’s three platforms; refuse with appeal rejected, or miss the deadline → listing revoked, with relisting only via a fresh application through the standard listing process.
  • Ongoing Self‑Check Duty: Enterprises must monitor prices in other provinces and submit price adjustment applications through the subsystem within 30 days of any new lower winning or listing price taking effect elsewhere.

Sector Background

  • Linkage Price Mechanism: Cross‑province price linkage forces listed and VBP‑winning prices toward the national lowest benchmark, a core pillar of China’s drug price governance that compresses inter‑provincial price gaps.
  • “Four‑Same” Targeting: Identical generic name, brand, dosage form and specification — the tightest comparability standard, closing arbitrage where the same product holds different prices across platforms.
  • Three‑Platform Unification: Confirmed “Four‑Same” adjustments apply uniformly across Guangdong’s three procurement platforms, eliminating within‑province price fragmentation.
  • Contact Channels: Online customer service via the Guangdong Drug Exchange Center website; hotlines 020‑87709875 / 020‑38036197 (weekdays 8:30–12:00, 14:00–17:30).

Market Impact & Outlook

  • Immediate Revenue Risk: For affected products, linkage adjustment means direct price cuts in Guangdong, one of China’s largest pharmaceutical markets — material for enterprises with concentrated provincial exposure.
  • Compliance Deadline Pressure: The four‑day window (closing 20 Sep, 17:00) makes timely CA‑certificate login and price confirmation operationally critical; missed deadlines trigger disqualification or delisting without further recourse.
  • National Price Discipline: The 30‑day self‑reporting duty institutionalizes continuous downward price surveillance — enterprises should embed cross‑province price monitoring into routine market‑access operations.
  • Strategic Considerations: Companies facing steep linkage cuts must weigh confirmation against withdrawal economics per product, factoring in relisting costs and the risk of setting new national price precedents.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding linkage price adjustments, appeals outcomes and potential disqualification or delisting of listed drugs in Guangdong. Actual price changes depend on enterprise confirmations, appeal adjudications and system data as of the batch cut‑off date, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100576933975691264